FOR THE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED Ph+ CML-CP
AND ADULTS WITH RESISTANT OR INTOLERANT Ph+ CML-CP/AP
TAKE ON Ph+ CML
Help patients reach their treatment goals with TASIGNA® (nilotinib)
‘‘
I relied on the skyhook.
‘‘ InIn basketball,
treating my Ph+ CML, I rely on TASIGNA.
- KAREEM ABDUL-JABBAR
NBA LEGEND
Kareem Abdul-Jabbar is an actual Ph+ CML patient taking TASIGNA and is compensated by Novartis.
INDICATIONS
• TASIGNA® (nilotinib) is indicated for the treatment of newly diagnosed adult patients with Philadelphia chromosome–positive chronic myeloid leukemia
(Ph+ CML) in chronic phase. The effectiveness of TASIGNA is based on major molecular response and cytogenetic response rates
• TASIGNA is indicated for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant to or intolerant to prior therapy that
included imatinib. The effectiveness of TASIGNA is based on hematologic and cytogenetic response rates
WARNING: QT PROLONGATION AND SUDDEN DEATHS
• TASIGNA prolongs the QT interval. Prior to TASIGNA administration and periodically, monitor for hypokalemia or hypomagnesemia and correct
deficiencies. Obtain ECGs to monitor the QTc at baseline, 7 days after initiation, and periodically thereafter, and following any dose adjustments
• Sudden deaths have been reported in patients receiving nilotinib. Do not administer TASIGNA to patients with hypokalemia, hypomagnesemia,
or long QT syndrome
• Avoid use of concomitant drugs known to prolong the QT interval and strong CYP3A4 inhibitors
• Avoid food 2 hours before and 1 hour after taking dose
IMPORTANT SAFETY CONSIDERATIONS
• Myelosuppression: Treatment with TASIGNA can cause Grade 3/4 thrombocytopenia, neutropenia, and anemia. Complete blood counts should be performed every
2 weeks for the first 2 months and then monthly thereafter
• Cardiac and Arterial Vascular Occlusive Events: Cases of cardiovascular events included ischemic heart disease-related events, peripheral arterial occlusive
disease, and ischemic cerebrovascular events have been reported
• Pancreatitis and Elevated Serum Lipase: TASIGNA can cause increases in serum lipase. Caution is recommended in patients with a history of pancreatitis
• Hepatotoxicity: The use of TASIGNA may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase
Ph+ CML, Philadelphia chromosome–positive chronic myeloid leukemia; CP, chronic phase; AP, accelerated phase.
Please see additional Important Safety Information and brief summary of Prescribing Information,
including Boxed WARNING, on the following pages.